Products04

Our multi-specific immuno-oncology drug ND021 holds the promise to outperform first generation checkpoint modulators in terms of safety and efficacy.

Pipeline

Hit discovery
Lead optimization
Preclincal PoC
IND-enabling studies
Phase I
ND009 (anti-TNF) IBD Partner: Tillotts
ND021 (ANTI-PDL1/41BB/hSA) Immuno-oncology
ND016 (multispecific) Chronic inflammation Partner: Intarcia
ND026 (multispecific) Chronic inflammation Co-development with Kaken
ND023 (multispecific) Immuno-oncology Partner: Ono
ND017 Metabolic disease Partner: Intarcia
Multiple programs (multispecific) Immuno-oncology

ND009 – IBD

ND021 – Immuno-oncology

ND016 – autoimmunity

ND026 – inflammation

ND023 – Immuno-oncology

ND017 – metabolic disease

ND009 – IBD

ND009 is an anti-TNF antibody fragment that is being developed for inflammatory bowel disease (IBD), a chronic inflammation of the digestive tract that primarily includes ulcerative colitis and Crohn’s disease. Anti-TNF therapy has been shown to reduce the need for hospitalization and surgical interventions in IBD and improve quality of life. Numab’s highly stable antibody fragment ND009 has best-in-class potency, and is licensed to Tillotts Pharma AG for the development and commercialization of innovative formulations.

ND021 – Immuno-oncology

ND021 is a next generation multi-specific immuno-oncology program targeting the tumor-immunity suppressive PD(L)-1 pathway and the tumor-immunity activating 4-1BB/CD137 pathway in a single therapeutic molecule. Targeting these two clinically validated pathways in a combinatorial approach is expected to provide patients suffering from a broad range of cancer types with a unique novel treatment opportunity characterized by an improved benefit-to-risk profile as compared to current standard of care as well as other combinatorial immunotherapy approaches currently in clinical development. The differentiating profile of ND021 is based on its molecular design as a monovalent trispecific antibody fragment aimed at highly effective, while only local activation of a tumor-directed specific immune response.

Download Poster presentation at AACR Annual Meeting 2018

 

ND016 – autoimmunity

ND016 is a novel multispecific antibody fragment-based molecule for the treatment of severe autoimmune disorders. In close collaboration with Intarcia Numab is developing a highly potent and stable lead molecule suitable for long-term sustained release from Intarcia’s miniaturized implantable Duros device, aiming at a once- or twice-yearly therapy. Intarcia retains the rights to commercialize this asset under license from Numab.

ND026 – inflammation

In ND026, Numab, together with its partner Kaken Pharmaceutical Co., Ltd., is developing a multi-specific immunomodulatory therapy for inflammatory disorders.

ND023 – Immuno-oncology

ND023 is a collaboration project partnered with Ono Pharmaceutical Co., Ltd., (the originator of the anti-PD1 antibody Nivolumab/Opdivo®) aimed at the discovery of a multi-specific antibody fragment-based molecule for immuno-oncology.

ND017 – metabolic disease

ND017 is a novel antibody fragment-based molecule for the treatment of metabolic disorders. Numab is developing a highly potent and stable lead molecule suitable for long-term sustained release from Intarcia’s miniaturized implantable Duros device, aiming at a once- or twice-yearly therapy. Intarcia retains the rights to commercialize this asset under license from Numab.

Our websites uses Google Analytics and cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our privacy statement.
Accept